The Specifics Of Speed: How To Reach The Clinic Faster While Maintaining Precision

If biologic sponsors can identify strategics for reaching the clinic faster, they can outpace their competition, maximize their product’s commercial lifespan, and most importantly, sooner grant patients access to life-saving treatments. But the pathway from DNA to IND is rife with challenges, and success relies on making the right decisions early, aligning development activities with long-term goals, and eliminating risks that could lead to delays down the road.

In a recent webinar hosted by Lonza, experts discussed how leaner process development, parallel workflows, and stronger platforms can reduce the mAb timeline to IND to as little as six months. Their post-webinar Q&A discussion provided greater insight into the fundamentals of this acceleration, including new expression vector systems and using robust pool material data. Download the full article to explore Lonza’s approach to enabling speed throughout development.